BioNTech (NASDAQ:BNTX) Given New $136.00 Price Target at HSBC

BioNTech (NASDAQ:BNTX) had its price target raised by HSBC from $97.00 to $136.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the stock.

BNTX has been the topic of a number of other reports. Jefferies Financial Group raised BioNTech from a hold rating to a buy rating and boosted their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. TD Cowen dropped their target price on BioNTech from $98.00 to $85.00 and set a hold rating on the stock in a report on Tuesday, August 6th. HC Wainwright increased their target price on BioNTech from $113.00 to $150.00 and gave the stock a buy rating in a research note on Monday. Deutsche Bank Aktiengesellschaft lifted their price target on BioNTech from $95.00 to $150.00 and gave the stock a buy rating in a research report on Thursday, September 19th. Finally, Bank of America increased their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a buy rating in a research report on Monday, September 16th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $131.92.

BioNTech Trading Up 0.8 %

NASDAQ:BNTX opened at $118.37 on Monday. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a 50-day moving average price of $100.13 and a 200-day moving average price of $93.16. The stock has a market cap of $28.14 billion, a price-to-earnings ratio of 236.74 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the prior year, the business posted ($0.86) EPS. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. Equities analysts predict that BioNTech will post -2.87 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of the company. Harding Loevner LP purchased a new stake in BioNTech during the fourth quarter valued at $410,984,000. Capital World Investors increased its position in shares of BioNTech by 0.5% during the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock valued at $87,002,000 after purchasing an additional 4,369 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after purchasing an additional 24,426 shares during the period. Candriam S.C.A. boosted its holdings in shares of BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after buying an additional 341,311 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.